Pfizer
PFE
27.78
-0.23
-0.80%
Pfizer
US · PFE
#133 by market cap
Listed 1970
27.78
-0.23
-0.80%
Live - 5344 symbols - heartbeat 222s ago
· 2026-10-08 09:40
Pre-market
27.85
-0.54%
After-hours
27.98
-0.06%
Overnight
28.00
0.00%
- Market cap
- 158.31B
- P/E (TTM)i
- 36.55
- P/Bi
- 1.86
- EPSi
- 1.36
- Div yieldi
- 6.19%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on PFE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 14 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 68.36% +0.04pp
- Institutions
- 3,273 -14
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund55.54%
Public Company4.59%
Private Company2.82%
Government Pension Fund1.93%
Hedge Fund1.19%
Sovereign Wealth Fund1.15%
VC/PE Fund0.31%
Insurance Company0.30%
Family Office/Trust0.29%
Other31.88%
Top holders as of 2026-06-30
BlackRock
9.29% · 529.67M sh
Vanguard Capital Management, LLC
7.09% · 404.16M sh
State Street Global Advisors
5.39% · 307.09M sh
Geode Capital Management, LLC
2.37% · 135.28M sh
Vanguard Portfolio Management, LLC
2.09% · 119.24M sh
Other
73.76%
Fisher Investments
1.91% · 109.07M sh
Morgan Stanley
1.20% · 68.22M sh
Norges Bank Investment Management
1.08% · 61.51M sh
Northern Trust Global Investments
1.04% · 59.08M sh
MFS Investment Management
0.99% · 56.55M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 44 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Albert Bourla | Chairperson & CEO | 0.01% |
| G. Dolsten | Chief Scientific Officer and President of Research & Development | 0.00% |
| Sally Susman | Executive VP & Chief Corporate Affairs Officer | 0.00% |
| Douglas Lankler | Executive Vice President | 0.00% |
| Chris Boshoff | Executive VP and Chief Oncology Research & Development Officer | 0.00% |
| Cecile Guegan | Senior VP & Head of Biopharma Group Finance | 0.00% |
| Michael McDermott | Executive VP & Chief Global Supply Officer | 0.00% |
| Ronald Blaylock | Independent Director | 0.00% |
| Dennis Hancock | Executive Vice President | 0.00% |
| Lidia Fonseca | Executive VP and Chief Digital & Technology Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +21 | -- |
| 2026-09-24 | Shantanu Narayen | Lead Independent Director | Other Derivative Acquisition | +1,743 | -- |
| 2026-09-24 | James Smith | Independent Director | Other Derivative Acquisition | +1,569 | -- |
| 2026-09-24 | Mortimer Buckley | Director | Other Derivative Acquisition | +1,307 | -- |
| 2026-09-24 | James Robert Quincey | Independent Director | Other Derivative Acquisition | +1,351 | -- |
| 2026-09-24 | Cyrus Russi Taraporevala | Director | Other Derivative Acquisition | +1,307 | -- |
| 2026-09-24 | Joseph Echevarria | Independent Director | Other Derivative Acquisition | +1,613 | -- |
| 2026-09-14 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +22 | -- |
| 2026-08-30 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +21 | -- |
| 2026-08-16 | Cecile Guegan | Senior VP & Head of Biopharma Group Finance | Initial Statement of Beneficial | 0 | -- |
| 2026-08-13 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +22 | -- |
| 2026-08-11 | Albert Bourla | Chairperson & CEO | Open Market Acquisition | +38,000 | $26.34 |
| 2026-08-04 | Ronald Blaylock | Independent Director | Open Market Acquisition | +39,231 | $25.46 |
| 2026-08-04 | Mortimer Buckley | Director | Open Market Acquisition | +37,632 | $25.52 |
| 2026-08-04 | Jennifer Damico | Officer | Open Market Disposition | -3,278 | $25.40 |
| 2026-07-30 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +24 | -- |
| 2026-07-14 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +24 | -- |
| 2026-07-08 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +84 | -- |
| 2026-06-29 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +25 | -- |
| 2026-06-25 | Shantanu Narayen | Lead Independent Director | Other Derivative Acquisition | +2,058 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:40:14 · For reference only, not investment advice and not tailored to your situation.